The Q2 2022 quarterly report can be accessed using the link below

Learn More

Dedicated to the treatment of inflammatory, fibrotic and metabolic diseases using our drug discovery platform and data-driven approach

Browse our resources hub for the latest news and information

Learn More

About us

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform and data-driven approach.

Read More

Product pipeline

Our expertise in small molecules has enabled a strong pipeline with potential first/best-in-class drug candidates.

Read More

Investors

Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.

Read More